With Chapter 11 proceedings underway, Dendreon Corp. is in the market for a buyer, but there likely isn’t any company interested in owning a prostate cancer treatment that never found its place in a now-crowded market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?